This book is a cutting-edge resource that provides clinicians with the up-to-date practical knowledge required in order to manage SCC patients optimally. It summarizes newly available information relating to the definition of high-risk SCC, its pathophysiologic underpinnings, and its management. New prognostic information and staging systems are summarized that enable high-risk tumors to be defined more precisely than ever before. Many helpful tips are provided on the practical management of challenging cases, including multiple tumors/field cancerization, high-risk tumors, nodal metastases, and unresectable disease. The authors are all acknowledged experts in the emerging field of high-risk and advanced SCC.
Rezensionen / Stimmen
"This book explores the immune and epigenetic mechanisms responsible for the development of squamous cell carcinoma. . The audience is dermatologists and oncologists. . When faced with a patient with a high-risk squamous cell carcinoma, this is the reference to turn to for the most up-to-date, multidisciplinary approach." (Patricia Wong, Doody's Book Reviews, August, 2016)
Auflage
Softcover reprint of the original 1st ed. 2016
Sprache
Verlagsort
Verlagsgruppe
Zielgruppe
Illustrationen
32
3 s/w Abbildungen, 32 farbige Abbildungen
XII, 255 p. 35 illus., 32 illus. in color.
Maße
Höhe: 235 mm
Breite: 155 mm
Dicke: 14 mm
Gewicht
ISBN-13
978-3-662-56891-0 (9783662568910)
DOI
10.1007/978-3-662-47081-7
Schweitzer Klassifikation
Chrysalyne Schmults, MD, MSCE
Director, Mohs & Dermatologic Surgery Center
Brigham & Women's Hospital
Department of Dermatology
1153 Centre St., Suite 4349
Jamaica Plain, MA 02130, USA
1. Introduction.- 2. DEFINING THE PROBLEM OF HIGH-RISK SCC: Epidemiology and Outcomes of SCC/Scope of The Problem.- 3. The Evidence For Clinical and Histologic Risk Predictors.- 4. Tumor Staging Systems and Prognostic Stratification.- 5. THE SCIENCE OF SCC: Molecular/Genetic Underpinnings of Tumorormation/Progression/Metastasis/Immunosurveillance.- 6. MANAGEMENT: Management of Patients With Multiple Sccs/Field Cancerization.- 7. Management of High-Risk Primary Tumors.- 8. Management of Extensive Local Recurrence/In-Transit Metastasis.- 9. Management of Nodal Metastases.- 10. Management of Widely Metastatic and Unresectable Disease.
